1Barbara J M, Connie S S. Persistent hantavirus infections:characteristics and mechanisms [J]. Trends in Microbiology, 2000, 8(2):61-66.
2Carralho N C, Gonzalez D V M O, Padula P J, et al.Cross-protection against challenge with Puumala virus after immunization with nucleocapsid proteins from different hantaviruses. J Virol, 2002, 76:6669-6677.
3Custer D M, Thompson E, Schmaljohn C S, et ai. Active and passive vaccination against Hanta virus pulmonary syndrome with andes virus M genome segment-based DNA vaccine[J]. J Virol, 2003,77(18):9894-9905.
4Elliott R M. The Bunyaviridae: Concluding remarks and future prospects. The Bunyaviridae[M]. New York: Plenum Press, 2003,295-332.
5Khaiboullina S F, Morzunov S P, St Jeor S C. Hantaviruses: molecular biology, evolution and pathogenesis[J]. Curr Mol Med, 2005,5:773-790.
6Koch J, Liang M, Queitsch I, et al. Human recombinant neutralizing antibodies against hantaan virus G2 protein [J]. Virology,2003,308(1) :64-73.
7Lu Q,Zhu Z, Weng Q. Immune responses to inactivated vaccine in people naturally infected with hanta viruses. J Med Virology, 2001,49:333.
8McCiain D J, Summers P L, Harrison S A, et al. Clinical evaluation of vaccinia-vectored Hanta virus vaccine[J]. J Med Virol, 2000,60(1):77-85.
9Oran A E, Robinson H L. DNA vaccines, combining form of antigen and method of delivery to raise a spectrum of IFN-gamma and IL-4-producing CD4+ and CD8+ T cells[J]. J Immunol, 2003,171 (4):1999-2005.
10Reyes-Sandoval A,Fitzgerald J C, Grant R, et al. Human immunodeficiency virus type 1-specific immune responses in primates upon seqaential immunization with adenoviral vaccine carriers of human and simian serotypes[J]. J Virol, 2004,78 (14) : 7392-7399.
